Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Mycobacterium tuberculosis and the response of its host
-
2. The pathogenesis of tuberculosis
- Dr. William R. Bishai
-
3. Immune response and rational development of vaccines and biomarkers
- Prof. Dr. Stefan H. E. Kaufmann
-
4. Molecular mechanisms of drug resistance in M. tuberculosis
- Dr. Daniela Cirillo
- The epidemiology of tuberculosis
-
5. The basic epidemiology of tuberculosis (TB)
- Dr. David Dowdy
-
6. Global epidemiology of TB
- Dr. Philippe Glaziou
-
7. Social determinants of tuberculosis
- Dr. Knut Lönnroth
- The control of tuberculosis
-
8. Treatment of tuberculosis
- Dr. Jean-Pierre Zellweger
-
9. The End TB Strategy towards TB elimination 1
- Dr. Mario Raviglione
-
10. The End TB Strategy towards TB elimination 2
- Dr. Mario Raviglione
-
11. Financing TB care and control
- Dr. Christopher Fitzpatrick
- Dr. Andrea Pantoja
-
12. Tuberculosis and COVID-19
- Prof. Giovanni Battista Migliori
-
13. Multidrug resistant tuberculosis (MDR-TB): an update
- Dr. Simon Tiberi
-
14. Impact of HIV on tuberculosis in the developing world and how to manage it
- Prof. Anthony D. Harries
-
16. TB in children
- Prof. Ben J. Marais
-
17. Community engagement in tuberculosis care
- Ms. Lana Syed
-
18. India: the epicentre of global TB control
- Dr. Madhukar Pai
-
19. Community engagement in TB care
- Dr. Haileyesus Getahun
- Research and development for new approaches in the control of tuberculosis
-
20. Development of new regimens for tuberculosis
- Dr. Zhenkun Ma
-
22. Pharmacometrics in tuberculosis
- Prof. Charles A. Peloquin
-
23. Extrapulmonary tuberculosis
- Dr. Scott Heysell
-
24. The role of surgery in tuberculosis management
- Dr. Richard Zaleskis
- Archived Lectures *These may not cover the latest advances in the field
-
25. The development of current treatments for tuberculosis
- Dr. Andrew Nunn
-
26. The pathogenesis of tuberculosis
- Dr. William R. Bishai
-
27. Basics of tuberculosis epidemiology
- Prof. Frank Cobelens
-
29. The international approach to the control of tuberculosis
- Dr. Mario Raviglione
-
30. Public-private mix for TB care and control
- Dr. Mukund Uplekar
Printable Handouts
Navigable Slide Index
- Introduction
- Biotech revolution
- TB diagnostic testing in endemic countries
- Microscope view of Ziehl–Neelsen stain preparation
- Poverty of the diagnostic test
- The slow road to microscopy diagnosis of TB (1)
- Where to put the efforts? (1)
- Cumulative TB mortality in sanitorium patients
- Smear positive patients are the most contagious
- DOTS implementation
- DOTS expansion didn't improve detection rates
- Limitations of increased case detection efforts
- DOTS reaching its limits
- The strategic need for early diagnosis
- Where to put the efforts? (2)
- TB notification in Zambia
- US MDR outbreaks
- TB case fatality rates
- Tugela Ferry DST survey
- Drug resistant TB in China
- TB is still endemic in the poorest countries
- TB is still poverty associated disease
- TB patients increasingly live in urban areas
- The slow road to microscopy diagnosis of TB (2)
- FIND: a public engine for diagnostic development
- TB assays may vary among laboratories
- Situation in 2004
- Situation in 2010
- Making EME standard accessible in DEC
- Fluorescence microscopy
- Laboratory capacity
- Hain test for molecular MDR screening
- 2007 evaluation of genotype MDRTB (1)
- 2007 evaluation of genotype MDRTB (2)
- Role of WHO endorsement for new technologies
- Increased speed and sensitivity of molecular tests
- Integrating the steps in NAAT
- Xpert MTB/Rif molecular beacon assay
- Simple sample processing (1)
- Simple sample processing (2)
- Detection of MTB from 3 samples per patient
- Rifampicin resistance detection
- Proportion of results reported over time
- Implementation of Xpert assays (1)
- Implementation of Xpert assays (2)
- Volume associated pricing for Xpert cartridges
- Xpert cartridge use in developing countries
- Decentralization of molecular diagnostics
- Next generation portable PCR devices
- TB LAMP procedure
- TB assays need to be extremely easy to perform
- Difficulties in developing rapid tests for TB
- MTB proteome screening for diagnostic antigens
- MBio system
- Whole cell detection
- Infection biomarker publications
- Declining rate of introduction of new protein tests
Topics Covered
- Tuberculosis: current diagnostics tests
- microscopy diagnosis in endemic countries
- the important distinction between smear negative and smear positive patients -introduction of DOTS
- limitations of DOTS
- TB notification in Zambia
- HIV and TB
- Drug resistant TB
- TB is a poverty associated disease
- The role of FIND in developing new diagnostic tests for TB
- Changes in TB testing from 2004 to 2010
- Novel testing methods for TB
- The role of WHO endorsements for new tests
- the Xpert assay
- Identification of biomarkers for TB
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Perkins, M. (2014, April 2). Development, testing and introduction of new diagnostic tools for tuberculosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/EUJT7962.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Mark Perkins has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Respiratory Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
Good day.
This is Mark Perkins.
I am the Chief Scientific
Officer of FIND, the Foundation
for Innovative New Diagnostics
here in Geneva, Switzerland.
Today we're going to be talking
about the development, testing,
and introduction of a new
diagnostic tools for tuberculosis,
an area in which there has been
considerable change in the last few years.
0:18
Over the past two decades there have been
remarkable improvements and changes
in biotechnology, specifically in
diagnostic testing; everything
from whole genome
bacterial sequencing
to handheld quantitative assays.
However, none of these changes
have led to diagnostic solutions
for communicable diseases for people
living in impoverished conditions.
Diseases linked to poverty
are still, basically,
insufficiently equipped, in too many settings.
0:45
A good example of this is
tuberculosis, a disease, which
for many years has relied on the same
fundamental diagnostic test -
the microscope.
Here is a picture of, in fact,
the microscope of Robert Koch.
And that microscope he used in 1882
to define TB in the first place
would look very much at home in a
modern laboratory in many countries
in the world.
1:08
This view through a
microscope looking
at a Ziehl-Neelsen stain
preparation is similar to what Koch
may have seen more
than 100 years ago.
The trouble with microscopy not
only is it relatively awkward,
burdensome to do and requires
a substantial training,
but it gives no
information about drug
susceptibility results or about the
species of the bacteria you see.
1:30
The result of this relative
poverty of the diagnostic test
is long delays in the
process of diagnosis itself.
Here's a picture at a routine
clinic, a diagnostic clinic,
in India where patients would
see to wait for the diagnosis
of the cause of their
prolonged cough.
True diagnostic delays often
runs to the three to nine months
period, resulting, of course,
in the ongoing transmission,
ongoing disease accrual.
What you see the
top of the slide are
numbers from the global
epidemiology of tuberculosis showing
in blue the relatively
large number of detected
and notified smear
positives-- 1.9 million--
and smear negative cases--
2.2 million-- and even larger
number of undetected or unreported
cases that don't get to the WHO.
Some of those are
detected and non-reported.
Some are non-detected.
And this adds to the large
number of TB mortality cases.
On the right, is the amount of
spending that we see not only
by patients and direct costs, but
by governments and loss of revenue
from tuberculosis and, specifically,
from the delayed diagnosis.
Hide